Skip to content

Study · In vitro (cells) · 2007

2 results

Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin.

Kidd M, Eick GN, Modlin IM, Pfragner R, Champaneria MC, Murren J

Journal of molecular endocrinology1 Feb 2007Cited by 39 (Europe PMC)

PMID17242179 (opens in a new tab)DOI10.1677/jme.1.02037 (opens in a new tab)PepBankPUB-17242179
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In KRJ-I cells, lanreotide inhibited stimulated serotonin secretion, with an IC50 of 420 nM.

    In plain wordsIn cells, lanreotide inhibited stimulated serotonin release from KRJ-I tumors, with an IC50 of 420 nM.

    Peptide
    Lanreotide
    Outcome
    DecreaseStimulated serotonin secretion
    Study

    humann: not reported in source

    KRJ-I neoplastic enterochromaffin cell line
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    IC50
    420 nM
    stimulated serotonin secretion

    Source sentences

    Summary
    Preincubation with a SSTR agonist, lanreotide, inhibited Ip-stimulated 5-HT secretion (IC50=420 nM).
    1 context sentence
    Summary · context
    We therefore further characterized the neoplastic SIC cell line, KRJ-I by assessing its secretory (serotonin (5-HT)) and proliferative responses and defining its log growth phase transcriptome.
  2. 02LabIn vitro (cells)Efficacy outcome

    In KRJ-I cells in serum-free medium, lanreotide inhibited proliferation by 20+/-12%.

    In plain wordsIn cells grown without serum, lanreotide reduced KRJ-I tumor cell proliferation by 20+/-12%.

    Peptide
    Lanreotide
    Outcome
    DecreaseCell proliferation
    Study

    humann: not reported in source

    KRJ-I neoplastic enterochromaffin cell line
    Outcome group
    Tumor growth · Gastrointestinal
    Studied dose
    10 nMAs given in this study (human).

    Measurements

    Proliferation inhibition
    20%
    lanreotide 10 nM, uncertainty reported in quote

    Source sentences

    Summary
    Both lanreotide (10 nM) and rapamycin (50 nM) inhibited proliferation (20+/-12 and 35+/-5% respectively) in serum-free medium
    1 context sentence
    Summary · context
    We therefore further characterized the neoplastic SIC cell line, KRJ-I by assessing its secretory (serotonin (5-HT)) and proliferative responses and defining its log growth phase transcriptome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.